Repligen Corporation Stock News

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati

Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.

Repligen (RGEN) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.64 per share a year ago.

WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi

Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best op

Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.

Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript

Repligen (RGEN) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.68 per share a year ago.

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f

Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET

Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two st